Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review

Summary Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS‐CoV‐2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS‐CoV‐2 vaccination doses were included in the study. One hundred and twenty‐four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety‐four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS‐CoV‐2 vaccination appears to be safe and effective in patients with ITP.